Bone metastasis in breast cancer: The story of RANK-Ligand

Journal of the Egyptian National Cancer Institute

Volumn 24, Issue 3, 2012, Pages 107-114

  Azim, Hamdy A ^a   Kamal, Nermine S ^a   Azim, Hatem A ^b  

^a Cairo University   (Egypt)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Bisphosphonates; Bone metastases; Breast cancer; Denosumab; Osteoclasts; Parathyroid hormone related protein; RANK ligand

Indexed keywords

AMGN 0007; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; PROTEIN INHIBITOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE DESTRUCTION; BONE METASTASIS; BONE REMODELING; BREAST CANCER; CHEMOTAXIS; DRUG MECHANISM; DRUG TARGETING; HUMAN; NONHUMAN; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; TRANSACTIVATION; TREATMENT OUTCOME;

ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RANK LIGAND; UP-REGULATION;

EID: 84865408290     PISSN: 11100362     EISSN: 16879996     Source Type: Journal    
DOI: 10.1016/j.jnci.2012.06.002     Document Type: Review

References (71)

1. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27:165-176.
2. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664.
3. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002, 4:30-34.
4. Aapro M., Abrahmsson P.A., Body J.J., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008, 19:420-430.
5. Khono N., Aogi K., Minami H., et al. Zoledronic acid significantly reduces skeletal related complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized placebo-controlled trial. J Clin Oncol 2005, 23:3314-3321.
6. Saad F., Olsson C., Schulman C.C. Skeletal morbidity in men with prostate cancer: quality of life considerations throughout the continuum of care. Eur Urol 2004, 46:731-739.
7. Wardely A., Davidson N., Barett-Lee P., et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomized, cross over study of community vs. hospital bisphosphonate administration. Br J Cancer 2005, 92:1869-1876.
8. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602.
9. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20:345-357.
10. Mundy G.R. Cytokines and growth factors in the regulation of bone remodeling. J Bone Miner Res 1993, 8:S505-S510.
11. Manolagas S.C., Jilka R.L. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995, 332:305-311.
12. Roodman G.D. Cell biology of the osteoclast. Exp Hematol 1999, 27:1229-1241.
13. Guisse T.A., Mohammad K.S., Clines G., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006, 12:6213s-6216s.
14. Khosla S. Minireview: the OPG/RANKL/RANK System. Endocrinology 2001, 142:5050-5055.
15. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
16. Li J., Sarosi I., Yan X.Q., Morony S., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000, 97:1566-1571.
17. Santini D., Schiavon G., Vincenzi B., et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One 2011, 6(4):e19234.
18. Jones D.H., Nakashima T., Sanchez O.H., et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692-696.
19. Dougall W.C. RANKL signaling in bone physiology and cancer. Curr Opin Support Palliat Care 2007, 1(4):317-322.
20. Roodman G.D. Biology of osteoclast activation in cancer. Journal of Clinical Oncology 2001, 19:3562-3571.
21. Tsukii K., Shima N., Mochizuki S., et al. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha, 25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun 1998, 246:337-341.
22. Yasuda H., Shima N., Nakagawa N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteclastogenesis in vitro. Endocrinology 1998, 139:1329-1337.
23. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
24. Bussard K.M., Gay C.V., Mastro A.M. The bone microenvironment in metastasis; what is special about bone?. Cancer Metastasis Rev 2007, 27:41-55.
25. Mundy G.R., DeMartino S., Rowe D.W. Collagen and collagen derived fragments are chemotactic for tumor cells. J Clin Invest 1981, 68:1102-1105.
26. Doerr M.E., Jones J.I. The role of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells. J Biol Chem 1996, 271:2443-2447.
27. Rossi D., Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000, 18:217-242.
28. Muller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
29. Li Y.M., Pan Y., Wei Y., et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004, 6:459-469.
30. Andre F., Xia W., Conforti R., et al. CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist 2009, 14:1182-1188.
31. Joyce J., Pollard J. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009, 9:239-252.
32. Guise T.A., Mundy G.R. Cancer and bone. Endocr Rev 1998, 19:18-54.
33. Kohno N., Kitazawa S., Fukase M., et al. The expression of parathyroid hormone-related protein in human breast cancer with skeletal metastases. Surg Today 1994, 24:215-220.
34. Bundred N.J., Walker R.A., Ratcliffe W.A., Warwick J., Morrison J.M., Ratcliffe J.G. Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer 1992, 28:690-692.
35. Guise T.A., Yin J.J., Taylor S.D., et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996, 98:1544-1549.
36. Henderson M., Danks J., Slavin J.L., et al. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res 2006, 66(4):2250-2256.
37. Isowa S., Shimo T., Ibaragi S., et al. PTHrP regulates angiogenesis and bone resorption via VEGF expression. Anticancer Res 2010, 30(7):2755-2767.
38. Ibaragi S., Shimo T., Iwamoto M. Parathyroid hormone-related peptide regulates matrix metalloproteinase-13 gene expression in bone metastatic breast cancer cells. Anticancer Res 2010, 30(12):5029-5036.
39. Onishi T., Hayashi N., Theriault R. Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol 2010, 7:641-651.
40. Bendre M.S., Gaddy-Kurten D., Mon-Foote T., et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 2002, 62:5571-5579.
41. Kominsky S., Davidson N.A. " Bone" fide predictor of metastasis? Predicting breast cancer metastasis to bone. JCO 2006, 24(15):2227-2229.
42. Fox S., Lovibond A. Current insights into the role of transforming growth factor-beta in bone resorption. Mol Cell Endocrinol 2005, 243:19-26.
43. Kiriyama T., Gillespie M.T., Glatz J.A., Fukumoto S., Moseley J.M., Martin T.J. Transforming growth factor b stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator?. Mol Cell Endocrinol 1992, 92:55-62.
44. Kingsley L., Fournier P., Chirgwin J. Molecular biology of bone metastasis. Mol Cancer Ther 2007, 6:2609-2617.
45. Bandyopadhyay A., Nichols R.W., Wang L., et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 2006, 66:6714-6721.
46. Ganapathy V., Ge R., Grazioli A., et al. Targeting the transforming growth factor-β pathway inhibits human basal-like breast cancer metastasis. Mol Cancer 2010, 9:122-137.
47. Duivenvoorden W.C., Hirte H.W., Singh G. Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis 1999, 17:27-34.
48. Prud'homme G.J. Pathobiology of transforming growth factor b in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007, 87:1077-1091.
49. Nagaraj N.S., Datta P.K. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs 2010, 19:77-91.
50. Silver I.A., Murrils R.J., Etherington D.J. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp Cell Res 1988, 175:266-276.
51. Brown E.M., Gamba G., Riccardi D., et al. Cloning and characterization of an extracellular Ca(+2)-sensing receptor from bovine parathyroid. Nature 1993, 366:575-580.
52. Cheng I., Klingensmith M.E., Chattopadhyay N., et al. Identification and localization of the extracellular calcium sensing receptor in human breast. J Clin Endocrinol Metab 1998, 83:703-707.
53. Mihai R. The calcium sensing receptor: from understanding parathyroid calcium homeostasis to bone metastases. Ann R Coll Surg Engl 2008, 90(4):271-277.
54. Mihai R., Stevens J., McKinney C., Ibrahim N. Expression of the calcium receptor in human breast cancer - a potential new marker predicting the risk of bone metastases. Eur J Surg Oncol 2006, 32:511-515.
55. Kitazawa S., Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 2002, 198:228-236.
56. Falzon M., Du P. Enhanced growth of MCF-7 breast cancer cells overexpressing parathyroid hormone-related peptide. Endocrinology 2000, 141:1882-1892.
57. Russell R.G. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 2006, 1068:340-367.
58. Fournier P.G., Stresing V., Ebetino F.H., Clézardin P. How do bisphosphonates inhibit bone metastasis in vivo?. Neoplasia 2010, 12(7):571-578.
59. Clezardin P. Potential anticancer properties of bisphosphonates: insights from preclinical studies. Anticancer Agents Med Chem 2012, 12(2):102-113.
60. Santini D., Martini F., Fratto M.E., et al. In vivo effects of zoledronic acid on peripheral gamma delta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009, 58:31-38.
61. Rosen L.S., Gordon D.H., Dugan W., et al. Zoledonic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004, 100:36-43.
62. Morony S., Warmington K., Adamu S., et al. The RANKL inhibitor osteoprotegerin (OPG) causes greater suppression of bone resorption and hypercalcaemia compared to bisphosphonates in two models of humoral hypercalcaemia of malignancy. Endocrinology 2005, 146:3235-3243.
63. Canon J.R., Roudier M., Bryant R., et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008, 25:119-129.
64. Body J.J., Greipp P., Coleman R.E. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003, 97:887-892.
65. Emery J.G., McDonnell P., Burke M.B., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998, 27:14363-14367.
66. Sheridan P., Marsters S.A., Pitti R.M., et al. Control of TRAIL induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277:818-821.
67. Neville-Webbe H.L., Cross N.A., Eaton C.L., Nyambo R., Evans C.A., Coleman R.E., Holen I. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL induced apoptosis. Breast Cancer Res Treat 2004, 86:269-279.
68. Arahamsen B., Teng A.Y. Technology evaluation: denosumab, Amgen. Curr Opin Mol Ther 2005, 7:604-610.
69. Stopeck A., Lipton A., Body J.J., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139.
70. Gonzalez-Suarez E., Jacob A.P., Jones J., et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107.
71. Schramek D., Leibbrandt A., Sigl V., et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102.